Supporting Information Figure 5. A2MG microvesicles reduce systemic and local pro-inflammatory cytokine levels during sepsis. Control microvesicles (cMV; 10^6 per mouse) or microvesicles containing A2MG (A2MG-MV) were administered i.v. at the indicated doses 5min prior to CLP (see Methods for details). Mice were sacrificed at 12h and peritoneal exudate cytokine levels were determined by multiplex ELISA. Results are mean±SEM. n = 5 mice per group (*P<0.05 vs. cMV treated mice by one way ANOVA)